Exencial Wealth Advisors LLC reduced its holdings in ARK Genomic Revolution ETF (ARKG) by 9.1% in the fourth quarter, according to the company’s most recent 13F filing with the SEC. The institutional investor owned 7,136 shares of the company’s stock after selling 715 shares during the quarter, with holdings worth $234,000 as of the filing.
Several other hedge funds also made changes to their positions in ARKG. BNP Paribas Financial Markets increased its stake by 112.8% in the fourth quarter, now owning 1,156,701 shares valued at $37,951,000. SG Americas Securities LLC and Del Sette Capital Management LLC also adjusted their positions, while Tower Research Capital LLC TRC and International Assets Investment Management LLC acquired new stakes in the ETF.
The stock of ARK Genomic Revolution ETF opened at $25.27 on Friday, with a 50-day moving average of $25.40 and a 200-day moving average of $28.46.
ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that primarily invests in genomics industry-related stocks. Launched on Oct 31, 2014, it is managed by ARK.
For more insights, you can check out institutional ownership data for ARK Genomic Revolution ETF (ARKG) in the provided chart. Subscribe to MarketBeat.com’s daily email newsletter for news and ratings on ARK Genomic Revolution ETF and related companies.